• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LEVODOPA Drug Record

  • Summary
  • Interactions
  • Claims
  • LEVODOPA chembl:CHEMBL1009 Approved

    Alternate Names:

    LARODOPA
    BENDOPA
    LEVODOPA
    BROCADOPA
    NSC-118381
    DOPAR
    V-1512
    INBRIJA
    (−)-DOPA
    L-BETA-(3,4-DIHYDROXYPHENYL)ALANINE
    Β-(3,4-DIHYDROXYPHENYL)-L-ALANINE
    L-3,4-DIHYDROXYPHENYLALANINE
    SINEMET®
    L-DOPA
    3-HYDROXY-L-TYROSINE
    LDP540
    LEVODOPUM
    3,4-DIHYDROXY-L-PHENYLALANINE
    Β-(3,4-DIHYDROXYPHENYL)ALANINE
    (−)-3-(3,4-DIHYDROXYPHENYL)-L-ALANINE
    DIHYDROXY-L-PHENYLALANINE
    chembl:CHEMBL1009
    drugbank:01235
    chemidplus:59-92-7
    rxcui:6375
    pubchem.compound:6047

    Drug Info:

    Drug Class antiparkinson agents
    Year of Approval approved before 1982
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antiparkinson agent
    (5 More Sources)

    Publications:

    Damasceno Dos Santos EU et al., 2019, Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease., J Clin Pharmacol
    Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J
    Koller et al., 1998, Mechanism of action of dopaminergic agents in Parkinson's disease., Neurology
    Onofrj et al., 2008, An expert opinion on safinamide in Parkinson's disease., Expert Opin Investig Drugs
    Deleu et al., 2002, Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease., Clin Pharmacokinet
    Zappia et al., 2005, Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study., Arch. Neurol.
    Kovoor et al., 2005, D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways., J. Neurosci.
    Mori et al., 2005, Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice., Neurosci. Res.
    Dupre et al., 2007, The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat., Brain Res.
    Schumacher-Schuh AF et al., 2014, Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients., Pharmacogenomics J
    St-Hilaire et al., 2006, Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice., Eur. J. Neurosci.
    St-Hilaire et al., 2005, Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism., Neurobiol. Dis.
    Gangemi et al., 2003, Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease., Mediators Inflamm.
    Joyce et al., 2004, Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment., Exp. Neurol.
    Adams et al., 1994, Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats., Exp. Neurol.
    Baraczka et al., 1983, Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration., J. Neural Transm.
    Pavón et al., 2006, ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice., Biol. Psychiatry
    Nash et al., 2005, Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia., FASEB J.
    Lee et al., 2006, A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats., Neuropharmacology
    Vila et al., 1997, Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA., J. Neurosci.
    Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
    Cheng et al., 1998, Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule., Am. J. Physiol.
    Takezako et al., 2001, Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine., J. Am. Soc. Nephrol.
    Moreau C et al., 2015, Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease., Brain
    Liu S et al., 2014, The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study., Pharmacogenet Genomics
    Liu et al., 2004, Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells., Neurochem. Res.
  • LEVODOPA   MT-CO1

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8987798


    Sources:
    NCI

  • LEVODOPA   DLG4

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15703272


    Sources:
    NCI

  • LEVODOPA   HOMER1

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24126708


    Sources:
    PharmGKB

  • LEVODOPA   IL15

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14514477


    Sources:
    NCI

  • LEVODOPA   DRD5

    Interaction Score: 0.53

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name entacapone/levodopa/carbidopa,Stalevo
    Novel drug target Established target
    Trial Name levodopa + carbidopa,Duodopa

    PMIDs:
    9633680 18549347 11978145


    Sources:
    TdgClinicalTrial

  • LEVODOPA   NR4A1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16930409 15896973


    Sources:
    NCI

  • LEVODOPA   DBH

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24809448


    Sources:
    PharmGKB

  • LEVODOPA   ADA

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11134247


    Sources:
    NCI

  • LEVODOPA   DRD3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D3 receptor agonist
    Direct Interaction yes
    Trial Name entacapone/levodopa/carbidopa,Stalevo

    PMIDs:
    30794329 27779245 9633680 18549347 11978145


    Sources:
    TdgClinicalTrial ChemblInteractions PharmGKB

  • LEVODOPA   DRD4

    Interaction Score: 0.16

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name entacapone/levodopa/carbidopa,Stalevo
    Novel drug target Established target
    Trial Name levodopa + carbidopa,Duodopa

    PMIDs:
    9633680 18549347 11978145


    Sources:
    TdgClinicalTrial

  • LEVODOPA   MTHFR

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12083967


    Sources:
    PharmGKB

  • LEVODOPA   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name DM-1992
    Novel drug target Established target
    Trial Name entacapone/levodopa/carbidopa,Stalevo

    PMIDs:
    27779245 15824260 15728856 15710490 18549347 9633680 11978145 17553470


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • LEVODOPA   SLC22A1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LEVODOPA   MAOB

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7867755 6420516


    Sources:
    NCI

  • LEVODOPA   TRPV1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16806299


    Sources:
    NCI

  • LEVODOPA   BAX

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15672541


    Sources:
    NCI

  • LEVODOPA   AGTR1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9458818


    Sources:
    NCI

  • LEVODOPA   SLC6A3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25805645


    Sources:
    PharmGKB

  • LEVODOPA   DRD1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name DM-1992
    Novel drug target Established target
    Trial Name entacapone/levodopa/carbidopa,Stalevo

    PMIDs:
    9633680 18549347 11978145


    Sources:
    DTC TdgClinicalTrial TEND

  • LEVODOPA   COMT

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LEVODOPA   BDNF

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15081599


    Sources:
    NCI

  • LEVODOPA   MAPK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16139809


    Sources:
    NCI

  • LEVODOPA   WRN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   BLM

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   MPHOSPH8

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   POLH

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   RECQL

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   APEX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   FEN1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   POLI

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   POLK

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   KDM4E

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   HSD17B10

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   KDM4A

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEVODOPA   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: LEVODOPA

    • Version: 01-August-2011

    Alternate Names:
    LEVODOPA Primary Drug Name

    Drug Info:
    Year of Approval approved before 1982
    Drug Class antiparkinson agents

    Publications:

  • TdgClinicalTrial: LEVODOPA

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiparkinson agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: L-DOPA

    • Version: 14-September-2017

    Alternate Names:
    C611 NCI drug code

    Drug Info:

    Publications:
    Nash et al., 2005, Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia., FASEB J.
    Takezako et al., 2001, Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine., J. Am. Soc. Nephrol.
    Cheng et al., 1998, Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule., Am. J. Physiol.

  • NCI: LEVODOPA

    • Version: 14-September-2017

    Alternate Names:
    C611 NCI drug code

    Drug Info:

    Publications:
    Liu et al., 2004, Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells., Neurochem. Res.
    Adams et al., 1994, Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats., Exp. Neurol.
    Vila et al., 1997, Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA., J. Neurosci.

  • PharmGKB: levodopa

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J
    Moreau C et al., 2015, Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease., Brain
    Damasceno Dos Santos EU et al., 2019, Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease., J Clin Pharmacol

  • TTD: Levodopa

    • Version: 2020.06.01

    Alternate Names:
    D08HVR TTD Drug ID

    Drug Info:

    Publications:

  • DTC: LEVODOPA

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1009 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1009

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1009

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21